XORTX Therapeutics Inc. announced the appointment of Stacy Evans, M.D., MBA, as Chief Business Officer. The engagement of Dr. Evans initiates a business development outreach program associated with the Company's XRx-008 program, with the goal of identifying a global partner for Phase 3 development and commercialization. In addition, XORTX has appointed Russo Partners as the Company's Public Relations firm, with David Melamed, Ph.D., as lead contact.

Stacy Evans, M.D., MBA, is an executive consultant with nearly 25 years of commercial development and business development experience, including 12 years at Pfizer where he led multiple transactions for Pfizer, including significant deal experience in the rare disease space. For the past seven years, Dr. Evans has consulted at an executive level with small to mid-size private and public biopharmaceutical companies, including acting as Chief Business Officer for many clients. Dr. Evans holds a M.D. from McGill University and an Executive MBA from Columbia University.